Paul Rohricht MS MBA

Vedere.Health is a boutique consulting firm specializing in helping early-stage technologies grow in the biotech, bio/pharma, and medical device spaces. ​ We provide expert, hands-on help in partnering, including in-/out-licensing, fundraising, and interim CEO and Senior BD&L services.

CROSS-BORDER BUSINESS DEVELOPMENT US bioConnect is a Philadelphia-based boutique cross-border business development firm that bridges the innovation that is discovered and developed by emerging companies in the Far East, with business and commercialization partners in the U.S. We manage our clients' cross-border interests with local representation for all types of transactions and services, including licensing, M and A, fundraising, joint ventures, manufacturing, and other strategic partnerships. Having local 'boots on the ground' allows for faster outcomes in deal-making...we will be your advocate and representative to drive the transaction to success. http://bit.ly/2PQd0bC

Vedere provides consulting to early and developmental stage technology companies, with a focus on biotechnology, medical device, and diagnostics. Vedere also provides interim CEO, COO, and short term interim management assignments, as well as business advisory and Board services. Overview of Selected Recent Projects: ► Entrepreneur in Residence, Wake Forest University Medical School (Wake Forest Innovations). Here, my role has been to survey all biomedical applications under development by Wake Forest researchers in order to assess suitability for a successful spinout as a standalone company. This included performing technical, IP, and commercial due diligence, and provide recommendations not only on what technologies could become viable spinouts, but also, what remaining milestones needed to be achieved in order to progress for those that required further maturation. For one selected opportunity from my review, I was asked to write a complete business plan for the spinout of a new technology in the oncology space. ► Confidential consultant to a billion dollar wound care company. In this nine-month project, I was tasked to review the entire would care portfolio, and develop an R&D and commercialization plan whereby new emerging technologies could be leveraged in order to a) Develop new products that “fit” in the current portfolio; b) Develop second generation products that incorporate new technologies that would enhance the value proposition of existing products; and c) Develop a roll out strategy including sales, marketing, and distribution in the U.S., Central America, EU and the Far East. ► Confidential consultant to a fast growing Nutraceutical company. In this project, I was tasked first to provide and IP review of a new area of business my client was intending to enter. This was followed by a technical review of the available scientific literature and assess the strength of claims that could be used in entering the new market.

Consultant to Wake Forest Innovations. Here, my role has been to survey all biomedical applications under development by Wake Forest researchers in order to assess suitability for a successful spinout as a standalone company. This included performing technical, IP, and commercial due diligence, and provide recommendations not only on what technologies could become viable spinouts, but also, what remaining milestones needed to be achieved in order to progress for those that required further maturation. For one selected opportunity from my review, I was asked to write a complete business plan for the spinout of a new technology in the oncology space.

Directed the day-to-day operations of Keraplast Technologies, as well as Keratec and RJK Developments, both wholly-owned subsidiaries based in New Zealand comprised of 25 professional technicians, research scientists, and administration. Managed a global network of independent distributors. P&L responsibility for the parent company and subsidiaries. Identified new opportunities to exploit Keraplast technology, including the identification of, and implementation of new revenue streams. Managed an IP estate of more than 140 issued and pending patents and trademarks. ► During my tenure as COO, the company went from a loss to an operating profit in less than 18 months. ► Restructured company's manufacturing facility leading to an operating profit during first year, accomplished by staff reduction, putting new procedures in place, raising prices, and reducing costs. ► Developed the company’s out-licensing strategy, identified suitable partners, negotiated and executed first supply and licensing agreement (including upfront fee, milestones, and royalty. Completed a second out-licensing and supply agreement that utilized Keraplast’s core patents and know-how. ► Wrote new business plan for the company that secured a $2.65M follow on funding from existing investors, an “up round” from the last funding completed in the fall of 2009. ► Launched direct sales of advanced wound care medical device products in the U.S., including the formation of a new subsidiary (Kerex, LLC). ► Authored, submitted, and awarded two Qualifying Therapeutic Discovery Program (QDTP) grants. ► Completed an agreement for distribution of Keraplast Advanced Wound Care products in Australia and New Zealand, with Catalyst Medical, and completed Joint Venture with Max Direct, LLC, which led to the formation of Keractive Beauty, LLC. Appointed as Board Member of Keractive Beauty, LLC, and served as the JV’s President, Secretary, and Treasurer.

In my Vice President of Business Development role, I designed and implemented the out-licensing strategy for company products in development; identified potential licensees, and executed licensing deals and R&D collaborations. Presented company technology and partnering interests at industry meetings. Communicated and coordinated activities and strategy with the Executive Management and Board of Directors. ► Developed the company’s out-licensing strategy, identified suitable partners, negotiated and executed first medical device development and licensing agreement with Siemens Medical Diagnostics Solutions (including upfront fee, milestones, and a revenue share agreement for worldwide commercialization of an undisclosed in vitro diagnostic technology). ► Co-invented and submitted two patent application to the USPTO for uses of technology under development at ICx Technologies, Inc., US Patent Application: unpublished, confidential. This patent was also filed with the EPO and is currently under review.

As Vice President of Business Development and member of the Executive Management team, I designed and implemented the out-licensing strategy for company products in development; and negotiated and completed out-licensing and R&D collaborations. Presented company technology and partnering interests at industry meetings. Communicated and coordinated activities and strategy with the Executive Management and Board of Directors. ► Developed the company’s out-licensing strategy, identified suitable partners, negotiated and executed company’s first partnering transaction with Biovitrum AB, a 50/50 co-development licensing agreement (including upfront fee, milestones, and a revenue share agreement for worldwide commercialization of Sym001, anti-D polyclonal antibody). ► Submitted and was awarded a 3 year, $5M grant with NIH (NIAID) for company’s second product in its pipeline, Sym002, anti-vaccinia polyclonal antibody. ► Completed a new discovery transaction with Meiji Seika Kaisha, a mid-sized Japanese pharmaceutical company. In addition to standard licensing terms (upfront fee, milestones, and royalties), Symphogen retained a co-development option in the U.S. and EU markets after the completion of the first Phase II clinical trial. ► Co-led and completed a new discovery transaction with Genentech valued at more than $330M and included standard licensing terms (upfront fee, milestones, and royalties). ► Led, planned, and executed the establishment of Symphogen’s wholly owned U.S. subsidiary, Symphogen, Inc. (Breinigsville, PA).